The drug failed to hit its Phase III targets.
Novo's global diabetes study finds that only 29% of polled patients were asked what they thought about prescribed regimens.
Chronic disease patients seek online support and information, and show little love for branded websites.
Forest's cost-savings initiative is aimed at reducing operating expenses by $500 million, while Eisai said it's cutting 130 positions in the US and Europe.
Spectrum DNA says its genetic services are at the ready, even if 23andMe's are not.
The leukemia drug is staying on the market, but for a more restricted patient population.
The drugmaker says interim trial data meets FDA review requirements and is hoping for June 2014 approval.
Actavis shrinks its staff by 30%, and Bayer reduces its California footprint.
The agency's bad-ad warning letter calls the new violations "particularly troubling."
The patient population is small, at around 3,000, but the expected price tag is $330,000 a year.
Early clinical trial results indicate 81% of advanced melanoma patients survived for one year.
The catch is the difference between sales and revenues. Generics will continue to be a force, and small-audience drugs will become increasingly important.
Known as Breo Ellipta in the US, GlaxoSmithKline's Relvar Ellipta was approved by the EMA for asthma and COPD. The overall market is expected to continue to grow, but an NIH study indicates more patient conversations need to happen.
The US-only recall amounts to less than 1% of the company's inventory.
The current number is reported to hover around $4 billion.
The company says it will cut staff and costs, focus on big accounts and try to keep sales reps from leaving.
An investigational cardiovascular heart drug failed to reduce the risk of heart attack or stroke, a miss which some on Wall Street say raises questions about the drugmaker's ability to deliver in late-stage trials.
The company announced the layoffs Friday.
The FDA's Bad Ad group says the drugmaker misbranded its cholesterol drug during interviews on CNBC.
The company's pursuit of a tighter research focus follows a path very much like that of its peers.
A poll by consulting firm QPharma indicates doctors are in the dark about what needs to be reported and what will be revealed.
The drugmaker says 20 jobs, or 17% of its workforce, will be gone by the end of the year.
The "New Endo" will be one company on the outside, two on the inside.
The news is part of an ongoing reorg by the Swiss firm that is rumored to include selling off its animal health business.
A 15% increase in sales came on the back of HIV franchise meds Stribild and Complera/Eviplera.
Generic giant Teva refuted allegations that the CEO, Jeremy Levin, and the board of directors were at odds over the company's cost-saving maneuvers.
The company's hep. C drug Incivek peaked in 2011. Competition and pipeline drugs have forced the company to regroup.
The prostate cancer drug company is reportedly seeking a buyer to turn things around.
Based on its first three months on market, Tecfidera is one launch that's living up to its hype.
A court refuses to compel a government agency to schedule the firm's epilepsy drug, as the med's patent clock ticks.